Biolase Analyst Ratings

BenzingaOct 2, 2024 10:15 ET

Biolase Is Maintained at Buy by Ascendiant Capital

Dow JonesSep 3, 2024 06:34 ET

Biolase Price Target Cut to $2.00/Share From $3.50 by Ascendiant Capital

Dow JonesSep 3, 2024 06:34 ET

Biolase Analyst Ratings

BenzingaAug 12, 2024 13:27 ET

Benchmark Reiterates Speculative Buy on Biolase, Maintains $0.4 Price Target

BenzingaAug 12, 2024 13:27 ET

Biolase Buy Rating Affirmed Amid Growth Opportunities and Proactive Cost Management

TipRanksJun 3, 2024 06:05 ET

Maxim Group Downgrades Biolase (BIOL) to a Hold

TipRanksMay 15, 2024 07:51 ET

Biolase Analyst Ratings

BenzingaMay 14, 2024 11:45 ET

Biolase Analyst Ratings

BenzingaApr 1, 2024 05:40 ET

Biolase's Strong Q4 Performance and Positive 2024 Outlook Affirm Buy Rating

TipRanksMar 23, 2024 07:40 ET

Biolase Analyst Ratings

BenzingaMar 22, 2024 13:44 ET

Maxim Group Reaffirms Their Buy Rating on Biolase (BIOL)

TipRanksFeb 22, 2024 16:05 ET

Positive Clinical Trial Results and Successful Cost Optimization Initiatives Bolster Buy Rating for Biolase Despite Lowered Price Target

TipRanksNov 14, 2023 13:15 ET

Positive McGuire Study Results Boost Biolase's Market Potential and Justify Buy Rating

TipRanksNov 9, 2023 13:46 ET

Maxim Group Sticks to Their Buy Rating for Biolase (BIOL)

TipRanksJun 7, 2023 07:45 ET

Lake Street Adjusts Price Target on Biolase to $0.40 From $1.50, Maintains Buy Rating

MT NewswiresMay 31, 2023 09:51 ET

Lake Street Maintains Buy on Biolase, Lowers Price Target to $0.4

BenzingaMay 31, 2023 09:28 ET

Maxim Group Maintains Buy on Biolase, Lowers Price Target to $1

BenzingaMar 29, 2023 13:01 ET

Lake Street Remains a Buy on Biolase (BIOL)

TipRanksMar 29, 2023 09:36 ET

Benchmark Reiterates Speculative Buy on Biolase, Maintains $2 Price Target

BenzingaMar 29, 2023 07:58 ET